| |
Record |
Links |
|
Author  |
Antonelli, A.; Bocci, G.; Fallahi, P.; La Motta, C.; Martina Ferrari, S.; Mancusi, C.; Fioravanti, A.; Di Desidero, T.; Sartini, S.; Corti, A.; Piaggi, S.; Materazzi, G.; Spinelli, C.; Fontanini, G.; Danesi, R.; Da Settimo, F.; Miccoli, P. |
|
| |
Title |
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo |
Type |
Journal Article |
| |
Year |
2014 |
Publication |
The Journal of Clinical Endocrinology and Metabolism |
Abbreviated Journal |
J Clin Endocrinol Metab |
|
| |
Volume |
|
Issue |
|
Pages |
jc20132321 |
|
| |
Keywords |
|
|
| |
Abstract |
Context and Objective. We have studied the antitumor activity of a “pyrazolo[3,4-d]pyrimidine” compound (CLM3) proposed for a multiple signal transduction inhibition [including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor (VEGF) receptor (VEGFR) and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C (undifferentiated thyroid cancer) and in an ATC-cell line (AF). Design and Main Outcome Measures. CLM3 was tested: in primary ATC cells at the concentrations of 5, 10, 30, 50 muM; in 8305C cells, and in AF cells, at 1, 5, 10, 30, 50 or 100 muM; in AF cells in CD nu/nu mice. Results. CLM3 significantly inhibited proliferation of 8305C and AF cells, inducing also apoptosis. A significant reduction of proliferation with CLM3 in ATC cells (P < 0.01, ANOVA) was shown. CLM3 increased the percentage of apoptotic ATC cells dose-dependently (P < 0.001, ANOVA) and inhibited migration (P < 0.01) and invasion (P < 0.001). AF-cell line was injected sc in CD nu/nu mice and tumor masses became detectable 15 days after. CLM3 (50 mg/kg/die) inhibited significantly tumor growth (starting 16 days after the beginning of treatment). CLM3 significantly decreased the VEGF-A expression and microvessel density in AF tumor tissues. Furthermore, CLM3 inhibited EGFR, AKT and ERK1/2 phosphorylation and down-regulated cyclin D1 in 8305C and AF cells. Conclusions. The antitumor and antiangiogenic activity of a “pyrazolo[3,4-d]pyrimidine” compound (CLM3) is very promising in anaplastic thyroid cancer, opening the way to a future clinical evaluation. |
|
| |
Address |
Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy |
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
|
Place of Publication |
|
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
0021-972X |
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
PMID:24423321 |
Approved |
no |
|
| |
Call Number |
refbase @ admin @ |
Serial |
35477 |
|
| Permanent link to this record |
